摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-11-oxo-10,11-dihydrodibenzo[b,f][1, 4]thiazepine-8-carboxylic acid | 1020412-79-6

中文名称
——
中文别名
——
英文名称
2-chloro-11-oxo-10,11-dihydrodibenzo[b,f][1, 4]thiazepine-8-carboxylic acid
英文别名
2-Chloro-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid;8-chloro-6-oxo-5H-benzo[b][1,4]benzothiazepine-3-carboxylic acid
2-chloro-11-oxo-10,11-dihydrodibenzo[b,f][1, 4]thiazepine-8-carboxylic acid化学式
CAS
1020412-79-6
化学式
C14H8ClNO3S
mdl
——
分子量
305.741
InChiKey
ZTSKFXQHOBTFDG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    91.7
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES DES PROTÉINES DU NOYAU DE L'HÉPATITE B
    申请人:UNIV INDIANA RES & TECH CORP
    公开号:WO2015138895A1
    公开(公告)日:2015-09-17
    ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    摘要 本公开提供了部分具有对乙型肝炎病毒Cp具有变构效应的化合物。本文还提供了治疗病毒感染(如乙型肝炎)的方法,包括向需要的患者施用所述化合物。
  • CB-1 MODULATING COMPOUNDS AND THEIR USE
    申请人:Olsson Roger
    公开号:US20080090805A1
    公开(公告)日:2008-04-17
    Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or condition that would be alleviated, improved or prevented by administration of a compound that modulates a cannabinoid receptor comprising identifying a subject in need thereof and administering to said subject a therapeutically effective amount of a compound of Formula (I). Also disclosed herein are pharmaceutical compositions comprising a compound of Formula (I).
    本文披露了一种化合物的结构式(I)。同时也披露了使用结构式(I)的化合物调节大麻素受体活性的方法。此外,还披露了一种治疗疾病或症状的方法,该疾病或症状可以通过给予调节大麻素受体的化合物得到缓解、改善或预防,包括确定需要该方法的受试者,并向该受试者施用结构式(I)的化合物的治疗有效量。本文还披露了包含结构式(I)的药物组合物。
  • Hepatitis B core protein allosteric modulators
    申请人:Indiana University Research and Technology Corporation
    公开号:US10183936B2
    公开(公告)日:2019-01-22
    The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    本公开内容部分提供了对乙型肝炎病毒 Cp 具有异生效应特性的化合物。本文还提供了治疗病毒感染(如乙型肝炎)的方法,包括向有需要的患者施用所公开的化合物。
  • Hepatitis B core protein modulators
    申请人:Assembly Biosciences, Inc.
    公开号:US10377748B2
    公开(公告)日:2019-08-13
    The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    本公开内容部分提供了对乙型肝炎病毒 Cp 具有异生效应特性的化合物。本文还提供了治疗病毒感染(如乙型肝炎)的方法,包括向有需要的患者施用所公开的化合物。
  • HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
    申请人:Indiana University Research and Technology Corporation
    公开号:EP3116316B1
    公开(公告)日:2019-07-10
查看更多